Pharmacogenomics

YouScript Wins "Genomics Innovation Award" in 8th Annual MedTech Breakthrough Awards Program

Retrieved on: 
목요일, 5월 9, 2024
Medtech, Health, Pharmacogenomics, Software, EHR, The, Electronic health record, Prescription, Patient safety, Telehealth, Medical device, Patient, Patient satisfaction, Medicine, Organization, Nursing

SEATTLE, May 9, 2024 /PRNewswire/ -- YouScript, an Aranscia company, today announced that it has been selected as winner of the "Genomics Innovation Award" in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.

Key Points: 
  • SEATTLE, May 9, 2024 /PRNewswire/ -- YouScript , an Aranscia company, today announced that it has been selected as winner of the "Genomics Innovation Award" in the 8th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough , an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market.
  • YouScript's pharmacogenomics (PGx) software and solutions enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs.
  • Incorporating YouScript as part of a proactive personalized medication management program has been shown to help providers mitigate the potential for dangerous adverse drug events, including associated hospital and emergency department visits.
  • "We're honored to receive the 'Genomics Innovation Award' from MedTech Breakthrough and bring further awareness to our mission of helping providers improve patient safety and care," said Kristine Ashcraft, Founder and President, YouScript.

DoseMe Enables Precision Dosing at Independence Health System

Retrieved on: 
목요일, 5월 2, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Health Technology, Medical Devices, Data Analytics, Software, Hospitals, Genetics, Pharmacogenomics, Palliative care, Hospital, Cardiology, Elective surgery, Partnership, BCPS, Patient, Record, Doctor of Pharmacy, Physician, AUC, Excela Health, Pharmacist, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD) software, has announced its collaboration with Excela Health, now part of Independence Health System .

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD) software, has announced its collaboration with Excela Health, now part of Independence Health System .
  • This alliance will advance therapeutic drug monitoring and optimize pharmacogenetics integration into pharmacokinetic/pharmacodynamic (PK/PD) models as part of IHS’s precision dosing strategy and initiatives.
  • With five hospitals, nearly 1,000 healthcare providers and more than 7,000 employees, Independence Health System serves a ten county region and is the largest employer in Butler and Westmoreland counties.
  • For more information on precision dosing models offered by DoseMe, visit https://doseme-rx.com/why-dosemerx/drug-packages

Second Opinion Expert Announces Strategic Relationship With Genome International

Retrieved on: 
월요일, 4월 1, 2024
Diagnosis, Genomics, SOE, Pharmacogenomics, Genome, Patient, Clinical decision support system, Research, Hospital, Laboratory, Whole genome sequencing, Medicine, CDSS, Therapy, Physician, Antibiotics

LOS ANGELES, April 1, 2024 /PRNewswire/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that it has entered into a strategic relationship with Genome International to provide rapid Whole Genome Interpretation (WGI™) delivered by Genome Explorer®, a comprehensive Clinical Decision Support System that brings genomic information to the point of care.

Key Points: 
  • We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide.
  • SOE will assist Genome International with business development and strategy, leveraging SOE's relationships and expertise.
  • Genome Explorer® provides a single unified platform for whole genome variant interpretation with high accuracy and success across diseases.
  • "We are proud to be part of Genome International's revolutionary effort to put the power of the genome in the hands of healthcare practitioners worldwide."

MEDITECH to Spotlight Intelligent Interoperability at HIMSS24

Retrieved on: 
목요일, 3월 7, 2024
Technology, Nanotechnology, Health, Other Health, Artificial Intelligence, Practice Management, Medical Devices, Software, Managed Care, Hospitals, Genetics, Hardware, Data Management, Nursing, Cloud, Google Cloud, FDB, Cardiac catheterization, AI, Structuring, Intelligence, API, Pharmacogenomics, Clinical trial, Cancer Moonshot, FHIR, EHR, SMART, Patient, MEDITECH, OLIS, Electronic health record, FAST, Representational state transfer

As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.

Key Points: 
  • As a longtime interoperability leader and advocate, MEDITECH is once again excited to feature its latest interoperability innovations in the HIMSS Interoperability Showcase.
  • MEDITECH will present its interoperability strategy at the Interoperability Showcase Spotlight Theater on Wednesday, March 13 at 11:15 a.m. in the “Intelligent Interoperability” session.
  • “Intelligent interoperability opens the doors to innovation by leveraging the flexibility and scalability of the cloud , along with modern and open data standards like SMART apps and FHIR APIs.
  • MEDITECH will also share its Canadian interoperability strategy at the “Achieving a Collaborative Approach to Meaningful Interoperability Across Canada” session.

FDB Showcases How to Elevate the Clinician Experience at HIMSS24

Retrieved on: 
목요일, 3월 7, 2024
Leapfrog, FDB, NCH, Pharmacogenomics, Hospital, Research, CDS, Physician, Orange County Convention Center, DDI, Pharmacy, EHR, Level 3, First Databank, Wine, Conference, Pharmacist, Risk, FACP, Safety, Exhibition, Organization, UMS, Social prescribing, Health, Patient, Patient safety, Prescription, Medicine, Workflow, Nursing

SOUTH SAN FRANCISCO, Calif., March 7, 2024 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, will showcase how provider organizations can elevate the clinician experience at the 2024 HIMSS Global Health Conference & Exhibition in Orlando, March 11-15. Through patient-specific clinical decision support (CDS), simplified patient instructions that help lead to better medication adherence, and a more flexible ePrescribing network that enables the smooth flow of prescriptions between prescribers, payers, and pharmacies, FDB is helping solve major challenges for healthcare delivery organizations today.

Key Points: 
  • Attendees at a HIMSS24 education session and visitors to FDB booth #1747 in the HIMSS24 exhibit hall will discover how leading hospitals and health systems are using FDB PatientFirst™ solutions.
  • HIMSS24 attendees will learn how NCH (Naples Comprehensive Health) used FDB Targeted Medication Warnings with FDB AlertSpace® to elevate the experience of its physicians and to improve patient safety and Leapfrog CPOE test results.
  • These CDS Heroes are on a mission to ignite actionable guidance, transform clinician workflows, elevate patient safety and outcomes, and banish alert overload for a better clinician experience.
  • "Elevate Your Experience": Unwind with Wine, Beer & Gourmet Popcorn
    HIMSS24 attendees are invited to join FDB for a casual in-booth reception to network with industry experts and peers.

NCPDP Foundation Opens Its Call for Grant Proposals, Due April 30

Retrieved on: 
수요일, 2월 28, 2024
Innovation, Digital therapeutics, Pharmacogenomics, Social, Pharmacist, Chesley Bonestell, MST, Health, Patient safety, Fund, Medicine, HL7, Trustee, Arrangement, Request, Standard, Value, Role, Single-frequency network, Health equity, Pharmaceutical industry

SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation. Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.

Key Points: 
  • SCOTTSDALE, Ariz., Feb. 28, 2024 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced its call for grant proposals that demonstrate the value of NCPDP standards in supporting the expanded role of pharmacists, patient safety, access to care, and coordination of care and innovation.
  • Proposals must meet the grant proposal requirements and be submitted electronically by 5:00 p.m. MST on April 30, 2024, to be considered for the current grant funding cycle.
  • Grant projects must benefit at least one of the NCPDP Foundation strategic initiatives: expanding the role and value of the pharmacist ; expanding patient access to care ; enhancing patient safety ; and empowering coordination of care and innovation, its newest strategic initiative.
  • To submit a grant proposal, complete and submit the Request for Funding form along with supplemental material by 5:00 p.m. MST on April 30, 2024.

Golden Helix is Launching VSPGx

Retrieved on: 
월요일, 2월 26, 2024
Pharmacology, Award, Hospital, SBIR, Pharmacogenomics, Genetics, Patient, NIH, Video game

BOZEMAN, Mont., Feb. 26, 2024 /PRNewswire/ -- Golden Helix, Inc. announces the release of VSPGx, a pharmacogenomics solution for hospitals and testing labs.

Key Points: 
  • BOZEMAN, Mont., Feb. 26, 2024 /PRNewswire/ -- Golden Helix, Inc. announces the release of VSPGx, a pharmacogenomics solution for hospitals and testing labs.
  • Golden Helix partnered with the NIH, who awarded us with a phase 1 SBIR (Award 1R43HG013456 – 01) to develop a first product addressing a vast need for this type of solution in the marketplace," says Dr. Andreas Scherer, President and CEO of Golden Helix.
  • Golden Helix will share the latest advancements and updates, including the launch of VSPGx.
  • Other talks are covering topics such as whole genome analysis using long-read data and updates on Golden Helix CancerKB.

2024 Employee Benefit Plans: Focus on Costs, Mental health, Well-being

Retrieved on: 
월요일, 1월 29, 2024
Standard, Empire Life, Pharmacare, The Conference Board, Business, Government, Mental health, Conference Board of Canada, Genetic testing, Disease, Conference, COVID-19, Pharmacogenomics, Organization, Health

36% ranked cost containment as the top priority—a 17% increase compared to January 2023.

Key Points: 
  • 36% ranked cost containment as the top priority—a 17% increase compared to January 2023.
  • Today's cost-conscious climate makes it especially important for advisors and customers to clarify priorities, said Mark Sylvia, President and CEO of Empire Life.
  • We definitely see an increased emphasis on making sure employees can come to work feeling better, feeling healthy, feeling connected."
  • According to Black, 72% of businesses surveyed had a specific strategy to support mental health and 30% were adopting the National Standard for Psychological Health and Safety.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
수요일, 11월 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
화요일, 11월 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.